002004 华邦健康
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,915,490-2.02%11,594,59013,232,36612,431,12610,876,362
减:营业总成本2,650,0590.41%10,449,04411,557,13311,386,50610,041,053
    其中:营业成本1,859,1212.01%7,059,5247,874,0687,682,2576,421,314
               财务费用75,059-26.30%230,777207,490438,928594,829
               资产减值损失40-67.35%(380,091)(560,356)(138,335)(47,049)
公允价值变动收益1,075-519.74%1,199(4,837)8,51610,258
投资收益6,459-35.42%7,521441,485300,009245,510
    其中:对联营企业和合营企业的投资收益(5,243)-204.27%(28,839)425,722239,099158,642
营业利润285,774-23.40%926,5111,645,0001,333,6411,194,862
利润总额283,579-22.73%892,3881,622,6961,281,2461,165,083
减:所得税费用69,150-4.14%215,456495,488361,042270,078
净利润214,429-27.27%676,9321,127,207920,205895,006
减:非控股权益58,869-49.99%374,810693,724252,395243,275
股东净利润155,560-12.18%302,122433,484667,809651,731

市场价值指针
每股收益 (元) *0.079-12.18%0.1530.2190.3370.330
每股派息 (元) *----0.2200.2200.2200.220
每股净资产 (元) *5.173-1.21%5.1045.1485.1064.864
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容